Overview

Study Evaluating Refacto For Pharmacovigilance

Status:
Completed

Trial end date:
2010-01-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to investigate the effectiveness and safety of treatment with ReFacto under conditions of routine therapy. Furthermore a continuous benefit/risk assessment will be done.

Details

Lead Sponsor:

Wyeth is now a wholly owned subsidiary of Pfizer

Treatments:

Factor VIII